Larry O Arthur

US Patent:

6989263, Jan 24, 2006

Filed:

Nov 1, 1999

Appl. No.:

09/431607

Inventors:

Louis E. Henderson - Mt. Airy MD, US
Larry O. Arthur - Walkersville MD, US
William G. Rice - Frederick MD, US

Assignee:

The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC

International Classification:

C12H 7/04
C12H 7/06
C07C 321/00
C07D 207/444

US Classification:

435236, 435238, 568 21, 568 25, 548548

Abstract:

The present invention provides several classes of compounds which can be used to inactivate retroviruses, such as HIV-1, by attacking the CCHC zinc fingers of the viral nucleocapsid protein and ejecting the zinc therefrom. In addition, kits for identifying compounds that can react with CCHC zinc fingers of the nucleocapsid proteins of a large number of different retroviruses have also been developed. The kits of the present invention describe a set of specific tests and reagents that can be used to screen and identify compounds based on their ability to react with and disrupt retroviral zinc fingers in the viral NC proteins and, in turn, inactivate the retrovirus of interest.

US Patent:

57053316, Jan 6, 1998

Filed:

Jun 7, 1995

Appl. No.:

8/485833

Inventors:

Larry O. Arthur - Walkersville MD
Louis E. Henderson - Mt. Airy MD

Assignee:

The United States of America as represented by the Secretary Department
of Health & Human Services - Washington DC

International Classification:

C12Q 170

US Classification:

435 5

Abstract:

An antigen capture method, and an antigen capture assay diagnostic kit, for detecting the presence or concentration of HIV in a biological sample without interference from antigen-antibody immune complexes is provided. The lysate of a biological sample obtained from an animal is contacted with a detectable mount of an antibody specifically reactive with the nucleocapsid p7 antigen or an immunoreactive fragment of the p7 antigen for a time and under conditions sufficient for p7 antigen contained in the lysate to form a p7-antibody complex. The presence or concentration of this p7-antibody complex is determined to detect or quantitate the presence of HIV in the biological sample. Uses of this assay and method include detecting the presence of HIV infection in an infant born to an HIV-infected mother, monitoring the progression of HIV infection, and evaluating the effectiveness of an anti-HIV treatment administered to an animal, such as a human. Purified antibodies specifically reactive with an immunoreactive epitope specific to p7 or an immunoreactive fragment of p7 are also provided as well as an antigen capture method for detecting the presence of a lentivirus in a biological sample involving the nucleocapsid protein of the lentivirus.

US Patent:

54628520, Oct 31, 1995

Filed:

Oct 28, 1992

Appl. No.:

7/967658

Inventors:

Larry O. Arthur - Walkersville MD
Louis E. Henderson - Mt. Airy, both od MD

Assignee:

The Government of the United States of America, as Represented by the
Secretary, DHHS - Rockville MD

International Classification:

C12Q 170

US Classification:

435 5

Abstract:

An antigen capture method, and an antigen capture assay diagnostic kit, for detecting the presence or concentration of HIV in a biological sample without interference from antigen-antibody immune complexes is provided. The lysate of a biological sample obtained from an animal is contacted with a detectable amount of an antibody specifically reactive with the nucleocapsid p7 antigen or an immunoreactive fragment of the p7 antigen for a time and under conditions sufficient for p7 antigen contained in the lysate to form a p7-antibody complex. The presence or concentration of this p7-antibody complex is determined to detect or quantitate the presence of HIV in the biological sample. Uses of this assay and method include detecting the presence of HIV infection in an infant born to an HIV-infected mother, monitoring the progression of HIV infection, and evaluating the effectiveness of an anti-HIV treatment administered to an animal, such as a human. Purified antibodies specifically reactive with an immunoreactive epitope specific to p7 or an immunoreactive fragment of p7 are also provided as well as an antigen capture method for detecting the presence of a lentivirus in a biological sample involving the nucleocapsid protein of the lentivirus.

US Patent:

60015551, Dec 14, 1999

Filed:

Jan 27, 1995

Appl. No.:

8/379420

Inventors:

Louis E. Henderson - Mt. Airy MD
Larry O. Arthur - Walkersville MD
William G. Rice - Frederick MD
Alan R. Rein - Takoma Park MD

Assignee:

The United States of America as represented by the Department of Health
and Human Services - Washington DC

International Classification:

C12Q 170

US Classification:

435 5

Abstract:

The present invention provides several classes of compounds which can be used to inactivate retroviruses, such as HIV-1, by attacking the CCHC zinc fingers of the viral nucleocapsid protein and ejecting the zinc therefrom. In addition, kits for identifying compounds that can react with CCHC zinc fingers of the nucleocapsid proteins of a large number of different retroviruses have also been developed. The kits of the present invention describe a set of specific tests and reagents that can be used to screen and identify compounds based on their ability to react with and disrupt retroviral zinc fingers in the viral NC proteins and, in turn, inactivate the retrovirus of interest.

US Patent:

56747209, Oct 7, 1997

Filed:

Jan 3, 1994

Appl. No.:

8/176682

Inventors:

Robert J. Gorelick - Braddock Heights MD
Larry O. Arthur - Walkersville MD
Alan Rein - Takoma Park MD
Louis E. Henderson - Mount Airy MD
Stephen Oroszlan - Potomac MD

Assignee:

United States of America - Washington DC

International Classification:

C12N 1300
C12P 2106
C07K 100
A61K 3921

US Classification:

4351723

Abstract:

The present invention defines a biological role for the following sequence of amino acids that is found in the nucleocapsid domain of the gag precursor polyproteins of all replication-competent retroviruses: -Cys-X-X-Cys-X-X-X-X-His-X-X-X-X-Cys- wherein X represents variable amino acids. The invariant residues constitute part of a vital protein structure, at least one of which are found in all retroviruses and which are involved in the selection and packaging of genomic viral RNA into infectious virus particles. Disruption of this structure leads to the formation of virus-like particles which appear to be structurally normal, but which do not contain the normal complement of viral RNA. Therefore, their infectivity is drastically reduced or completely eliminated. The infectivity of any retrovirus, including human retroviruses, and more particularly human immunodeficiency virus (HIV), can be drastically reduced or completely eliminated by generating mutants that lack some or all of the invariant residues required to form the structure.